|Institutional Source||Beutler Lab|
|Gene Name||tumor necrosis factor (ligand) superfamily, member 15|
|Synonyms||TL1, VEGI, TL1A|
|Is this an essential gene?||Probably non essential (E-score: 0.053)|
|Stock #||R4595 (G1)|
|Chromosomal Location||63727084-63745113 bp(-) (GRCm38)|
|Type of Mutation||nonsense|
|DNA Base Change (assembly)||G to T at 63729943 bp (GRCm38)|
|Amino Acid Change||Tyrosine to Stop codon at position 153 (Y153*)|
|Ref Sequence||ENSEMBL: ENSMUSP00000050144 (fasta)|
|Gene Model||predicted gene model for transcript(s): [ENSMUST00000062246]|
|AlphaFold||no structure available at present|
AA Change: Y153*
AA Change: Y153*
|Meta Mutation Damage Score||0.9755|
|Coding Region Coverage||
|Validation Efficiency||94% (62/66)|
FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein is abundantly expressed in endothelial cells, but is not expressed in either B or T cells. The expression of this protein is inducible by TNF and IL-1 alpha. This cytokine is a ligand for receptor TNFRSF25 and decoy receptor TNFRSF21/DR6. It can activate NF-kappaB and MAP kinases, and acts as an autocrine factor to induce apoptosis in endothelial cells. This cytokine is also found to inhibit endothelial cell proliferation, and thus may function as an angiogenesis inhibitor. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Feb 2011]
PHENOTYPE: Homozygous targeted mutants display decreased clinical severity in experimental autoimmune encephalomyelitis (EAE) and collagen-induced arthritis. [provided by MGI curators]
|Allele List at MGI|
|Other mutations in this stock||
|Other mutations in Tnfsf15||
(F):5'- GGAACCAGTTGTTGCTTATTTCAC -3'
(R):5'- CAAGACTTTATTCTGATACCACAGG -3'
(F):5'- CACAGACTTGGACCCTGTTAGTAG -3'
(R):5'- CACAGGTATCAAAACCAGAGGTTCTG -3'